Igor A. Sherman
About
In The Last Decade
Igor A. Sherman
27 papers receiving 456 citations
Peers
Comparison fields: 5 of 86
- Surgery 165
- Hepatology 154
- Epidemiology 128
- Oncology 95
- Molecular Biology 72
Countries citing papers authored by Igor A. Sherman
This map shows the geographic impact of Igor A. Sherman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Igor A. Sherman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Igor A. Sherman more than expected).
Fields of papers citing papers by Igor A. Sherman
This network shows the impact of papers produced by Igor A. Sherman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Igor A. Sherman. The network helps show where Igor A. Sherman may publish in the future.
Co-authorship network of co-authors of Igor A. Sherman
This figure shows the co-authorship network connecting the top 25 collaborators of Igor A. Sherman. A scholar is included among the top collaborators of Igor A. Sherman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Igor A. Sherman. Igor A. Sherman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 1 | |
| 3 | 1 | |
| 4 | 1 | |
| 5 | Bivalent binding properties of epidermal growth factor receptor targeted monoclonal antibodies: Factors contributing to differences in observed clinical profiles. | 7 |
| 6 | 9 | |
| 7 | 1 | |
| 8 | 7 | |
| 9 | 1 | |
| 10 | Pharmacokinetics studies and toxicity profile of raltitrexed used by intraperitoneal route in normothermia in a pig model. | 4 |
| 11 | 11 | |
| 12 | 31 | |
| 13 | 23 | |
| 14 | 12 | |
| 15 | 2 | |
| 16 | The cardiovascular effects of gamma-hydroxybutyrate following hemorrhage. | 12 |
| 17 | 25 | |
| 18 | 67 | |
| 19 | 80 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.